|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2006
Lymphangioleiomyomatosis
Division of Therapeutics and Molecular Medicine, University Hospital, Queens Medical Centre, Nottingham, UK.
CORRESPONDENCE: S. R. Johnson, Division of Therapeutics and Molecular Medicine, University Hospital, Queens Medical Centre, Nottingham NG7 2UH, UK. Fax: 44 1159422232. E-mail: simon.johnson{at}nottingham.ac.uk
Keywords: Angiomyolipoma, interstitial disease, orphan disease, tuberous sclerosis
Received: October 9, 2003
Accepted March 31, 2004
Lymphangioleiomyomatosis (LAM) is a rare disease of the lungs and lymphatics, which can occur sporadically or in association with tuberous sclerosis. LAM almost exclusively affects females, generally developing before the menopause.
The disease is characterised by progressive pulmonary cystic change, recurrent pneumothorax, chylous pleural collections and, in most cases, progressive respiratory failure. Abdominal manifestations include lymphadenopathy, cystic lymphatic masses (lymphangioleiomyomas), chylous ascites and angiomyolipoma (a benign tumour). Survival in LAM is
Diagnosis is made by a combination of clinical features and computed tomography scanning or, in cases of doubt, lung biopsy. In patients with rapidly progressive disease, hormone treatment (predominantly progesterone) has been used, although no firm evidence supports its use. Otherwise, treatment is aimed at complications including pneumothorax, chylous collections and extrapulmonary manifestations. The only treatment for severe LAM is currently lung transplantation.
Recent developments in the cell biology of lymphangioleiomyomatosis have shown that these patients have somatic mutations in the genes linked to tuberous sclerosis and that rapamycin may correct the resulting cellular abnormality. Trials of rapamycin in lymphangioleiomyomatosis are currently underway and offer hope of evidence-based treatment for the disease.
70% at 10 yrs, although this is highly variable since long-term survivors have been described.
This article has been cited by other articles:
|
|
 |
|
  D A Muzykewicz, A Sharma, V Muse, A L Numis, J Rajagopal, and E A Thiele TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex J. Med. Genet., July 1, 2009; 46(7): 465 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Brant, M. S. Parker, L. K. Brath, and M. M. Grimes A 47-Year-Old Woman With Progressive Dyspnea and Recurrent Pneumothoraces Chest, May 1, 2009; 135(5): 1389 - 1394. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kanoh, H. Kobayashi, and K. Motoyoshi Bronchoscopic Blood Injection Reducing Lung Volume in Lymphangioleiomyomatosis Ann. Thorac. Surg., April 1, 2009; 87(4): 1266 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. J. Schmithorst, T. A. Altes, L. R. Young, D. N. Franz, J. J. Bissler, F. X. McCormack, B. J. Dardzinski, and A. S. Brody Automated Algorithm for Quantifying the Extent of Cystic Change on Volumetric Chest CT: Initial Results in Lymphangioleiomyomatosis Am. J. Roentgenol., April 1, 2009; 192(4): 1037 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Glassberg, S. J. Elliot, J. Fritz, P. Catanuto, M. Potier, R. Donahue, W. Stetler-Stevenson, and M. Karl Activation of the Estrogen Receptor Contributes to the Progression of Pulmonary Lymphangioleiomyomatosis via Matrix Metalloproteinase-Induced Cell Invasiveness J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1625 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Goncharova, D. A. Goncharov, A. Chisolm, M. S. Spaits, P. N. Lim, G. Cesarone, I. Khavin, O. Tliba, Y. Amrani, R. A. Panettieri Jr., et al. Interferon {beta} Augments Tuberous Sclerosis Complex 2 (TSC2)-Dependent Inhibition of TSC2-Null ELT3 and Human Lymphangioleiomyomatosis-Derived Cell Proliferation Mol. Pharmacol., March 1, 2008; 73(3): 778 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. X. McCormack Lymphangioleiomyomatosis: A Clinical Update Chest, February 1, 2008; 133(2): 507 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Young, Y. Inoue, and F. X. McCormack Diagnostic Potential of Serum VEGF-D for Lymphangioleiomyomatosis N. Engl. J. Med., January 10, 2008; 358(2): 199 - 200. [Full Text] [PDF]
|
|
|
|
 |
|
 V. P. Krymskaya Smooth Muscle like Cells in Pulmonary Lymphangioleiomyomatosis Proceedings of the ATS, January 1, 2008; 5(1): 119 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Ryu, C. E. Daniels, T. E. Hartman, and E. S. Yi Diagnosis of Interstitial Lung Diseases Mayo Clin. Proc., August 1, 2007; 82(8): 976 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Watz, K. Engels, S. Loeschke, M. Amthor, D. Kirsten, and H. Magnussen Lymphangioleiomyomatosis--presence of receptor tyrosine kinases and the angiogenesis factor VEGF-A as potential therapeutic targets Thorax, June 1, 2007; 62(6): 559 - 559. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D'Armiento, K. Imai, J. Schiltz, N. Kolesnekova, D. Sternberg, K. Benson, A. Pardo, M. Selman, T. Smolarek, M. Vundavalli, et al. Identification of the Benign Mesenchymal Tumor Gene HMGA2 in Lymphangiomyomatosis Cancer Res., March 1, 2007; 67(5): 1902 - 1909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zarogiannis, C. Hatzoglou, P. A. Molyvdas, and K. Gourgoulianis Lymphangioleiomyomatosis Eur. Respir. J., December 1, 2006; 28(6): 1284 - 1284. [Full Text] [PDF]
|
|
|
|
|
|
T. B. L. Ho, J. H. Hull, and N. C. Hughes An 86-year-old female with lymphangioleiomyomatosis. Eur. Respir. J., November 1, 2006; 28(5): 1065 - 1064. [Full Text] [PDF]
|
|
|
|
|
|
C. Vogelmeier and U. Costabel Much ado about nothing? Eur. Respir. J., May 1, 2006; 27(5): 880 - 880. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |